Categories: NeurologyNews

NeuroXT and BIDMC Join Forcesto Revolutionize Alzheimer’s Treatment with AI

New Partnership Aims to Tailor Alzheimer’s Treatments Using Cutting-Edge AI Technology

BOSTON, Aug. 22, 2024 /PRNewswire/ — In a groundbreaking move that could transform Alzheimer’s treatment, NeuroXT, a leading biotechnology startup, has partnered with Beth Israel Deaconess Medical Center (BIDMC), a teaching hospital affiliated with Harvard Medical School. Together, they are set to revolutionize how Alzheimer’s is treated by developing AI-driven imaging biomarker solutions that predict treatment success.

With recent FDA approvals of promising Alzheimer’s drugs like Eisai’s Leqembi and Eli Lilly’s Kisunla, there is renewed hope in the fight against this challenging disease. However, these treatments are not without their hurdles—ranging from inconsistent results to potential side effects. NeuroXT aims to overcome these obstacles by harnessing the power of AI to deliver personalized treatment strategies.

NeuroXT’s state-of-the-art technology uses MRI data to understand the interaction between beta-amyloid and tau proteins—key players in Alzheimer’s disease. This innovative approach has the potential to tailor treatment plans to each patient, dramatically improving outcomes and minimizing side effects.

This research, led by Daniel Press, MD, Chief of the Cognitive Neurology Unit at Beth Israel Deaconess Medical Center, aims to enhance treatment effectiveness and proactively improve treatment monitoring, including amyloid reduction monitoring and Amyloid-Related Imaging Abnormalities (ARIA) side effects, a common concern in recent trials.

About NeuroXT

NeuroXT is at the forefront of biotechnology, focusing on AI-driven solutions for neurological conditions. Under the leadership of CEO Sung Joon-kyung, NeuroXT is committed to advancing Alzheimer’s treatment through precision medicine. Their cutting-edge AI imaging biomarker technology is designed to predict individual treatment responses, ensuring the best therapeutic window for each patient.

Contact:
Martin Hyun 
NeuroXT 
808-354-9669 
382148@email4pr.com 

For more details on NeuroXT’s AI-driven innovations and its partnership with BIDMC, visit www.neuroxt.com or contact us directly.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neuroxt-and-bidmc-join-forcesto-revolutionize-alzheimers-treatment-with-ai-302227444.html

SOURCE NeuroXT

Staff

Recent Posts

AGAPE ATP Corporation Addresses Recent Corporate Exercise and Strategic Developments

Reverse Stock Split and New Initiatives to Drive Future Growth KUALA LUMPUR, MALAYSIA / ACCESSWIRE…

1 hour ago

Quantum Biopharma Announces Celly Nutrition Launches unbuzzd(TM) Grab-and-Go Stick Packs on Amazon.com so you can “own NOW and what’s NEXT”

TORONTO, ON / ACCESSWIRE / August 30, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma"…

1 hour ago

SS Innovations Issues Update on Status of Audit Process and Trading Market for Common Stock

FORT LAUDERDALE, Fla., Aug. 30, 2024 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company”…

1 hour ago

Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness

For the second year, Emergent is teaming up with pro football legend, Emmitt Smith, to…

1 hour ago

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage…

1 hour ago

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September

NAARDEN, The Netherlands and MIAMI, Aug. 30, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V.…

1 hour ago